Canada markets closed
  • S&P/TSX

    20,269.97
    +89.37 (+0.44%)
     
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • DOW

    34,152.01
    +239.61 (+0.71%)
     
  • CAD/USD

    0.7784
    +0.0031 (+0.40%)
     
  • CRUDE OIL

    87.13
    +0.60 (+0.69%)
     
  • BTC-CAD

    30,765.74
    -295.87 (-0.95%)
     
  • CMC Crypto 200

    569.15
    -2.76 (-0.48%)
     
  • GOLD FUTURES

    1,790.40
    -7.70 (-0.43%)
     
  • RUSSELL 2000

    2,020.53
    -0.82 (-0.04%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • NASDAQ futures

    13,663.50
    -17.75 (-0.13%)
     
  • VOLATILITY

    19.69
    -0.26 (-1.30%)
     
  • FTSE

    7,536.06
    +26.91 (+0.36%)
     
  • NIKKEI 225

    28,868.91
    -2.87 (-0.01%)
     
  • CAD/EUR

    0.7651
    +0.0026 (+0.34%)
     

IDEXX Laboratories' (NASDAQ:IDXX) investors will be pleased with their splendid 122% return over the last five years

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) shareholders might understandably be very concerned that the share price has dropped 34% in the last quarter. But that doesn't change the fact that shareholders have received really good returns over the last five years. Indeed, the share price is up an impressive 122% in that time. To some, the recent pullback wouldn't be surprising after such a fast rise. Only time will tell if there is still too much optimism currently reflected in the share price. Unfortunately not all shareholders will have held it for the long term, so spare a thought for those caught in the 45% decline over the last twelve months.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

View our latest analysis for IDEXX Laboratories

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During five years of share price growth, IDEXX Laboratories achieved compound earnings per share (EPS) growth of 26% per year. The EPS growth is more impressive than the yearly share price gain of 17% over the same period. So one could conclude that the broader market has become more cautious towards the stock.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
earnings-per-share-growth

It might be well worthwhile taking a look at our free report on IDEXX Laboratories' earnings, revenue and cash flow.

A Different Perspective

While the broader market lost about 20% in the twelve months, IDEXX Laboratories shareholders did even worse, losing 45%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 17%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with IDEXX Laboratories .

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting